# US 2023/0054595 A1 · Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054595 A1
- Document ID: US20230054595A1
- Status: Published application
- Kind: A1
- Application number: 17/787,433
- Filed: 2020-12-18
- Published: 2023-02-23
- Earliest claimed: 2019-12-18
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Struan Grant; Andrew Wells; Chun Su
- Web page: https://patentgrep.com/patent/US20230054595A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Compositions and methods for the management and treatment of inflammatory disorders including SLE are disclosed.

## Claims

### Claim 1

A method for alleviating inflammatory disease symptoms in a patient in need thereof, comprising;
a) identifying in a nucleic acid containing biological sample from said patient, an inflammatory disease GWAS causal variant in a gene which is indicative of the presence of, or increased risk for, inflammatory disease;
b) treating said patient with an effective amount of at least one agent which targets said gene harboring said causal variant, thereby alleviating inflammatory disease symptoms.

### Claim 2 (depends on 1)

The method of claim 1, wherein said inflammatory disease is selected from systemic lupus erythematosus (SLE), arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison's disease, Vitiligo, asthma, scleroderma, systemic sclerosis, or allergic asthma.

### Claim 3 (depends on 1)

The method of claim 1, wherein said inflammatory disease is SLE.

### Claim 4 (depends on 1)

The method of claim 1, wherein proximal and sentinel SNPs, inferred GWAS causal variant and genes implicated in 3D epigenomics assays are listed in Table 1.

### Claim 5 (depends on 4)

The method of claim 4, wherein implicated genes and suitable therapeutic are listed in Table 2.

### Claim 6 (depends on 4)

The method of claim 4, wherein said gene is MINK1 and the agent is a MAP3/4K antagonist.

### Claim 7 (depends on 1)

A method for identifying an agent useful for the treatment of inflammatory disease for use in the method of claim 1, comprising;
a) providing a cell harboring at least one gene comprising an informative SNP for inflammatory disease in a cell type of interest and a cell which lacks said informative SNP;
b) incubating said cells in the presence with an agent; and
c) identifying agents which alter the function of said gene in cells harboring said SNP relative to those lacking said SNP.

### Claim 8 (depends on 1)

The method of claim 1, wherein said cells are selected from tonsil follicular T helper cells, naïve CD4+ T cells, naïve CD8+ T cells, memory CD4+ T cells, memory CD8+ T cells, cytotoxic T lymphocytes, naïve B cells, germinal center B cells, Th1 cells, Th2 cells, Th17 cells, NK cells, dendritic cells, monocytes

### Claim 9 (depends on 7)

The method of claim 7, wherein said gene and said agent is provided in Table 2.

### Claim 10

A method for treatment of SLE comprising administration of an effective amount of
i) a MAP3/4K antagonist; or,
ii) a pharmacological inhibitor of HIPK1; said treatment alleviating SLE symptoms.

### Claim 11 (depends on 10)

The method of claim 10, wherein said agent is PF06260933.

### Claim 12 (depends on 10)

The method of claim 10, further comprising administration of a steroid.

### Claim 13

(canceled)

### Claim 14 (depends on 7)

A transgenic mouse which is a knockout mouse for HIPK1 or MINK1 for use in the method of claim 7.

### Claim 15 (depends on 7)

The method of claim 7, wherein said agent is screened in a transgenic mouse comprising a nucleic acid harboring a loss of function mutation in HIPK1 or MINK1.

### Claim 16 (depends on 1)

An EBV transformed cell line harboring at least one gene comprising an informative SNP for an inflammatory disease in a cell type of interest as claimed in claim 1, wherein said gene is encoded by
i) a nucleic acid comprising a mutation in a HIPK1 gene isolated from a patient having altered immune function, or
ii) a mutation in a nucleic acid comprising a MINK1 gene isolated from a patient having altered immune function, or
iii) a nucleic acid harboring a mutation in a gene listed in Table 1.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)
